In an ongoing sign indicating how difficult the capital raising environment is for medtech startups, a new venture capital report found that venture capital investment in 2013 fell once again.
Medical device firms garnered only about $2.12 billion last year, down from $2.55 billion in 2012, according to the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association using data from Thomson Reuters. Across all industries however, the story was different. Overall, venture capitalists pumped $29.4 billion into startups in 2013, up from $27.3 billion in 2012.In the last quarter of the year, the medical devices sector received $459.8 million, down from $631.3 million in the fourth quarter of 2012.While medical devices had a weak showing in 2013 continuing a similar theme from the year before, biotech venture investment actually climbed slightly to $4.54 billion, up from $4.19 billion.
The number of deals in medical devices also fell. In 2013, the volume fell to 308 deals from 322 in 2012.
Here were the top five medical devices deals of 2013:
Mevion Medical Systems, which provides proton beam therapy raised $55 million from CHL Medical Partners,ProQuest Investments,Venrock and undisclosed investors.
ReVision Optics, which provides a refraction optical surgery to correct presbyopia, raised $54.7 million from Canaan Partners, ,Domain Associates,InterWest Partners, ,Johnson & Johnson Development Corp, Rossiyskaya Korporatsiya Nanotekhnologiy GK and ProQuest Investments
ConforMIS, which makes custom total knee replacement systems, raised nearly $54 million from Agc Equity Partners Ltd and undisclosed investors.
Nevro, which makes spinal cord stimulation therapies, raised $48 million from Accuitive Medical Ventures, Bay City Capital,Covidien Ventures, Johnson & Johnson Development Corp, MPM Capital,New Enterprise Associates,Novo A/S,Three Arch Partners, and an undisclosed investor.
Spinal Modulation, which makes an implantable spinal cord stimulator to treat chronic pain, raised $45 million from De Novo Ventures, Johnson & Johnson Development Corp., Kleiner Perkins Caufield & Byers, Medventure Associates and undisclosed investors.
– By Arundhati Parmar, Senior Editor,